RecruitingPhase 3NCT06666764
Normobaric Oxygen in AIS Transferred for EVT
Adjuvant Normobaric Hyperoxia in Acute Ischemic Stroke Patients Transferred for Thrombectomy
Sponsor
Capital Medical University
Enrollment
1,500 participants
Start Date
Dec 13, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The primary objective of this study is to estimate the efficacy and safety of NBO on 3-month functional outcome after acute ischemic stroke
Eligibility
Min Age: 18 Years
Inclusion Criteria10
- Age at least 18 years old;
- Signs and symptoms are consistent with a new acute stroke, with low possibility of stroke mimics (e.g., no sudden coma, prior seizure disorder, suspected hypoglycemia);
- No prior stroke in the last 3 months;
- Time from stroke onset (last seen well) to randomization is within 9 hours;
- (1) Baseline NIHSS score at 6 or more and Intracranial ICA or MCA-M1 or MCA-M2 dominant occlusion, with or without tandem cervical carotid stenosis or tandem cervical occlusion, confirmed by preoperative CTA (or MRA, DSA) and consistent with signs and symptoms; or (2) Baseline NIHSS score at 6 or more with a hyperdense MCA sign on non-contrast CT; or (3) Baseline NIHSS score at 12 or more;
- NIHSS score 0 or 1 in the section of level of consciousness;
- No significant pre-stroke disability (pre-stroke mRS 0--1);
- ASPECTS at least 6 on non-contrast CT;
- Patient is planned for transfer to a EVT-capable hospital for EVT;
- Signed informed consent from the patient or the legally authorized representative (LAR).
Exclusion Criteria15
- Known history of severe chronic obstructive pulmonary disease (FEV1 less than 1.0), New York Heart Association (NYHA) Heart Failure Class III or IV, acute pulmonary infection or aspiration pneumonia, prior to enrollment;
- Respiratory rate <= 10 or >= 30 breaths per minute;
- Oxygen-dependence at baseline to maintain SaO2 > 95% or intubation at baseline;
- Seizure at stroke onset;
- Exhibiting symptoms of vomiting, or severe headache, or unconscious;
- Rapidly improving neurological deficits or transient ischemic attack prior to consent;
- Signs and symptoms suggestive of subarachnoid hemorrhage, even if CT scan is normal;
- Evidence of intracranial tumor (except small meningioma) or arteriovenous malformation;
- Woman of childbearing potential known to be pregnant or with a positive pregnancy test;
- Life expectancy < 90 days due to comorbidity;
- Unlikely to complete the 90-day follow-up;
- Participating in another clinical treatment trial, or completed participation within prior 30 days;
- Receiving other cerebral protective agent (e.g., edaravone dexborneol, n-butylphthalide);
- Evidence of acute intracranial hemorrhage on CT/MRI;
- Significant mass effect with midline shift, defined as any deviation of midline structures such as the septum pellucidum, is observed on CT/MRI scans.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERNBO
NBO will be conducted with inhalation of 100% oxygen.
OTHERControl
Best medical care
Locations(112)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06666764
Related Trials
Continuous Dual Aspiration Technique With Zoom System for Stroke
NCT074919529 locations
Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy
NCT0597668528 locations
Intra-arterial Tenecteplase for Acute Medium Vessel Occlusion Stroke
NCT073579871 location
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
NCT0506521666 locations
Direct Ischemic Conditioning for Endovascular Recanalization for Anterior Large Vessel Occlusion (DICER-aLVO)
NCT069401281 location